CUMBERLAND PHARMACEUTICALS REPORTS Q3 2026 FINANCIAL RESULTS & COMPANY UPDATE
CUMBERLAND PHARMACEUTICALS INC (CPIX) filed an SEC Form 8-K — Results of Operations and Financial Condition. CUMBERLAND PHARMACEUTICALS REPORTS Q3 2026 FINANCIAL RESULTS & COMPANY UPDATE $100 million Strategic Transaction Closed Plans to Submit New Drug Application for Ifetroban in DMD Top-Line Results Announced for Systemic Sclerosis Trial NASHVILLE, Tenn. (Nov. 10, 2026) – Cumberland
How this was made
The 30-second read
Why it matters
The 8‑K provides the first public disclosure of the Q3 results, cash position, and the upcoming NDA, which are likely to move the stock.
Market read
New financials and regulatory milestones create a fresh catalyst for CPIX, making the news highly relevant for traders.
What to watch
The $100 M transaction may dilute existing shareholders and the company’s cash burn could become a risk if further funding is needed.
Q3 2026 GAAP net income of $77,777,752 included an $81,092,578 gain on disposal of discontinued operations; continuing operations still reported an operating loss of $(1,936,482)
Reported net income is driven by a one-time gain on the Strategic Transaction classified in discontinued operations. Continuing operations reported a net loss of $(1,122,071) and an operating loss of $(1,936,482) for the quarter, with total revenue of $2,156,356, of which $1,950,000 is transition services revenue. The filing prints no prior-quarter figures and no guidance.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total revenue, Q3 2026 (three months ended Sept 30)GAAP | $2,156,356 | – | – |
| Transition services revenue, Q3 2026GAAP | $1,950,000 | – | – |
| Net revenue, Q3 2026GAAP | $206,356 | – | – |
| Cost of transition services, Q3 2026GAAP | $1,062,266 | – | – |
| Research and development, Q3 2026GAAP | $841,162 | – | – |
| General and administrative, Q3 2026GAAP | $2,182,285 | – | – |
| Amortization, Q3 2026GAAP | $7,125 | – | – |
| Total costs and expenses, Q3 2026GAAP | $4,092,838 | – | – |
| Operating loss, Q3 2026GAAP | $(1,936,482) | – | – |
| Interest income, Q3 2026GAAP | $822,886 | – | – |
| Interest expense, Q3 2026GAAP | $(4,604) | – | – |
| Loss before income taxes, Q3 2026GAAP | $(1,118,200) | – | – |
| Income tax expense, Q3 2026GAAP | $(3,871) | – | – |
| Net loss from continuing operations, Q3 2026GAAP | $(1,122,071) | – | – |
| Income (loss) from discontinued operations, Q3 2026GAAP | $(1,725,098) | – | – |
| Gain on disposal of discontinued operations, Q3 2026GAAP | $81,092,578 | – | – |
| Income tax expense on disposal of discontinued operations, Q3 2026GAAP | $(467,657) | – | – |
| Net income of discontinued operations, Q3 2026GAAP | $78,899,823 | – | – |
| Net income (loss), Q3 2026GAAP | $77,777,752 | – | – |
| Net income (loss) attributable to common shareholders, Q3 2026GAAP | $77,776,986 | – | – |
| Earnings (loss) per share, basic, Q3 2026GAAP | $5.19 | – | – |
| Earnings (loss) per share, diluted, Q3 2026GAAP | $5.07 | – | – |
| Continuing operations loss per share, basic, Q3 2026GAAP | $(0.07) | – | – |
| Continuing operations loss per share, diluted, Q3 2026GAAP | $(0.07) | – | – |
| Discontinued operations earnings per share, diluted, Q3 2026GAAP | $5.14 | – | – |
| Total revenue, nine months ended Sept 30, 2026GAAP | $2,486,665 | – | – |
| Transition services revenue, nine months ended Sept 30, 2026GAAP | $1,950,000 | – | – |
| Net revenue, nine months ended Sept 30, 2026GAAP | $536,665 | – | – |
| Cost of transition services, nine months ended Sept 30, 2026GAAP | $1,062,266 | – | – |
| Research and development, nine months ended Sept 30, 2026GAAP | $2,379,170 | – | – |
| General and administrative, nine months ended Sept 30, 2026GAAP | $7,128,677 | – | – |
| Amortization, nine months ended Sept 30, 2026GAAP | $21,276 | – | – |
| Total costs and expenses, nine months ended Sept 30, 2026GAAP | $10,591,389 | – | – |
| Operating loss, nine months ended Sept 30, 2026GAAP | $(8,104,724) | – | – |
| Interest income, nine months ended Sept 30, 2026GAAP | $961,802 | – | – |
| Interest expense, nine months ended Sept 30, 2026GAAP | $(5,394) | – | – |
| Loss before income taxes, nine months ended Sept 30, 2026GAAP | $(7,148,316) | – | – |
| Income tax expense, nine months ended Sept 30, 2026GAAP | $(11,611) | – | – |
| Net loss from continuing operations, nine months ended Sept 30, 2026GAAP | $(7,159,927) | – | – |
| Income (loss) from discontinued operations, nine months ended Sept 30, 2026GAAP | $(3,248,722) | – | – |
| Gain on disposal of discontinued operations, nine months ended Sept 30, 2026GAAP | $81,092,578 | – | – |
| Net income, nine months ended Sept 30, 2026GAAP | $70,216,272 | – | – |
| Net income attributable to common shareholders, nine months ended Sept 30, 2026GAAP | $70,210,971 | – | – |
| Earnings (loss) per share, basic, nine months ended Sept 30, 2026GAAP | $4.69 | – | – |
| Earnings (loss) per share, diluted, nine months ended Sept 30, 2026GAAP | $4.60 | – | – |
| Continuing operations loss per share, diluted, nine months ended Sept 30, 2026GAAP | $(0.46) | – | – |
| Net cash used in operating activities from continuing operations, nine months ended Sept 30, 2026GAAP | $(1,133,984) | – | – |
| Net cash provided by (used in) operating activities, nine months ended Sept 30, 2026GAAP | $(942,253) | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Transition services revenue (Q3 2026)The filing prints the figure and the prior-year value of $171,821 but does not state a driver. | $1,950,000 | – | – |
| Net revenue (Q3 2026)The filing prints the figure and a prior-year value of "—" but does not state a driver. | $206,356 | – | – |
Capital returns
- Cash dividend paid, nine months ended Sept 30, 2026: $(22,479,497). The 2025 column prints "—".
- Payments made in connection with repurchase of common shares, nine months ended Sept 30, 2026: $(318,820), compared with $(263,478) in the nine months ended Sept 30, 2025.
- Exercise of options and purchases of shares from employees, nine months ended Sept 30, 2026: $21,725. The 2025 column prints "—".
- The $100 million in proceeds at closing of the Strategic Transaction is described as having strengthened the balance sheet. The filing does not state how the proceeds are being allocated.
What drove it
- The filing states that revenues and expenses of the Strategic Transaction continued to be classified as discontinued operations in Q3 2026, and that net income for the quarter included the gain on divestiture of the assets associated with the Strategic Transaction.
- The filing states that Q3 2026 was the company's first period of operations following the July 1, 2026 closing of the Strategic Transaction with Apotex Health, and that its commercial brands and organization were integrated into Apotex's U.S. branded business.
- Interest income from continuing operations was $822,886 for Q3 2026, compared with $131,583 in Q3 2025. The filing does not state a cause.
Concerns
- Continuing operations reported an operating loss of $(1,936,482) for Q3 2026 and $(8,104,724) for the nine months. Net loss from continuing operations was $(1,122,071) for the quarter.
- Reported Q3 2026 net income of $77,777,752 includes an $81,092,578 gain on disposal, which the filing classifies within discontinued operations. Discontinued operations also recorded a loss of $(1,725,098) in the quarter.
- Transition services revenue of $1,950,000 is the largest revenue line in Q3 2026. The filing does not state how long transition services revenue will continue.
- Risk factors in the forward-looking statements include that the FDA may refuse to file the NDA or may not approve ifetroban, that the FDA may require additional trials and data, and "the need for additional capital".
- Operating cash flow for the nine months was $(942,253) including discontinued operations, and $(1,133,984) from continuing operations.
- The release states that the SSc results will inform the company's decision on further development, and the filing gives no efficacy figures for that trial.
What to watch
- Timing and completion of the ifetroban NDA submission for cardiomyopathy associated with DMD under the FDA rolling review. The filing states the company has decided to submit the NDA but gives no submission date.
- FDA acceptance, review timeline and any priority review voucher eligibility, which the forward-looking statements say may not be realized.
- Submission of the clinical study report for the Phase 2a ASSIST-SSc trial, completion of correlative biomarker studies, and cardiac imaging evaluations, which will inform the decision on further SSc development.
- Continuing operations operating expense trends, including R&D of $841,162 and G&A of $2,182,285 in Q3 2026, and whether interest income continues to offset operating losses.
- Use of the approximately $80.6 million in cash and cash equivalents, given the $22,479,497 cash dividend paid in the nine months and the company's stated focus on its clinical pipeline.
Balance sheet and cash flow
- Cash and cash equivalents at Sept 30, 2026: $80,581,021, compared with $11,444,693 at Dec 31, 2025. The release also states "$80.6 million in cash and cash equivalents".
- Total assets at Sept 30, 2026: $113,779,293, compared with $76,823,992 at Dec 31, 2025. The release states "approximately $114 million in total assets".
- Total liabilities at Sept 30, 2026: $41,604,127, compared with $52,279,770 at Dec 31, 2025. The release states "$42 million".
- Total shareholders' equity at Sept 30, 2026: $72,505,965, compared with $24,880,322 at Dec 31, 2025. Total equity was $72,175,166 compared with $24,544,222. The release states "$73 million" for shareholders' equity.
- Net cash used in investing activities from continuing operations, nine months ended Sept 30, 2026: $(1,888,349), compared with $(679,577). Net cash provided by investing activities including discontinued operations was $98,095,906 (2025: $(1,633,159)).
- Net cash used in financing activities from continuing operations, nine months ended Sept 30, 2026: $(28,017,325), compared with $(5,032,581). The filing prints no free cash flow figure.
- Payments on line of credit, nine months ended Sept 30, 2026: $(5,240,733), compared with $(10,035,437).
Analysis
Cumberland's Q3 2026 release is the first quarterly report after the July 1, 2026 closing of its Strategic Transaction with Apotex Health. The filing keeps the transaction's revenues and expenses in discontinued operations, so the quarter's GAAP net income of $77,777,752 includes an $81,092,578 gain on disposal and a $(467,657) income tax expense on that disposal. Continuing operations show total revenue of $2,156,356, made up of transition services revenue of $1,950,000 and net revenue of $206,356, against total revenue of $171,821 in Q3 2025. The filing does not print a prior-quarter figure or a percentage change for revenue.
On continuing operations, total costs and expenses were $4,092,838, compared with $3,028,343 a year earlier. R&D rose to $841,162 from $646,473, while G&A fell to $2,182,285 from $2,376,284. Cost of transition services was $1,062,266, a line with no prior-year figure in the release. The operating loss narrowed to $(1,936,482) from $(2,856,522), and interest income increased to $822,886 from $131,583. Net loss from continuing operations was $(1,122,071), compared with $(2,730,638). The filing describes these as the results of continuing operations but does not explain the movements.
The balance sheet changed materially from December 31, 2025. Cash and cash equivalents rose to $80,581,021 from $11,444,693, total assets to $113,779,293 from $76,823,992, and shareholders' equity to $72,505,965 from $24,880,322. Liabilities fell to $41,604,127 from $52,279,770. For the nine months, the company paid a cash dividend of $(22,479,497) and repurchased shares for $(318,820). Operating cash flow was $(942,253) including discontinued operations, and $(1,133,984) from continuing operations.
The company also updated its pipeline. It said it will submit an NDA for ifetroban in cardiomyopathy associated with DMD, supported by Phase 2 FIGHT DMD data showing a 5.4 percentage point improvement in left ventricular ejection fraction (p=0.002) in the high-dose group, under an FDA rolling review. It also reported top-line Phase 2a ASSIST-SSc results, with the company stating that no serious adverse event during the 12-month treatment period was assessed as related to study drug. The company has not yet decided on further SSc development. The release contains no guidance for revenue, margins, expenses or tax.
Overall, the quarter's reported profit comes from a one-time disposal gain recorded in discontinued operations, while continuing operations still show an operating loss, a small net loss, and revenue made up mainly of transition services. The key figures for the reader are the $81,092,578 disposal gain, the $(1,936,482) continuing operations operating loss, and the $80,581,021 cash balance.
Management, verbatim
Our first full quarter as a development-focused company has reinforced the value of concentrating our efforts on our clinical pipeline.
A.J. Kazimi, CEO
Not in the filing
stated, not guessed- Company guidance for revenue, gross margin, operating expenses or tax rate was not provided, so the guidance field is null.
- Prior-quarter (Q2 2026) figures are not printed, so all qoq_change and prior_quarter fields are null.
- Percentage changes for total revenue, transition services revenue and operating lines are not printed, so yoy_change fields are null.
- Revenue segment breakdown beyond transition services revenue and net revenue is not printed.
- Free cash flow is not printed.
- Gross margin is not printed, and cost of transition services has no prior-year figure.
- Prior-year figures for the discontinued operations gain and related tax line are "—" in the filing.
- The efficacy figures for the ASSIST-SSc trial are not printed in the release.
- The timing of the ifetroban NDA submission is not given.
- Market reaction and analyst consensus figures are not provided in the documents.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Cumberland Pharmaceuticals recently completed a strategic transaction with Apotex Health, integrating its commercial brands and focusing on its clinical pipeline.
Ticker impact
Cumberland Pharmaceuticals filed an 8‑K reporting Q3 2026 results, a $100 M strategic transaction close and plans to submit an NDA for ifetroban in DMD.
likely upward pressure as market prices in the NDA filing and Phase 2 results
The filing provides fresh financials, a sizable cash infusion and a clear regulatory path, which are new material facts for investors.
Market effects
Strengthens the rare‑disease biotech sector with a new NDA pipeline candidate.
May boost investor sentiment toward US‑listed biotech stocks.
Adds to global biotech pipeline momentum, especially for DMD therapies.
Counterpoint
If the FDA raises concerns on safety or efficacy, the stock could face downside despite the positive data.
Key entities
- companyCumberland Pharmaceuticals Inc.
US‑listed biopharma developing rare‑disease therapies.
- companyApotex Health
Canadian pharmaceutical partner in the strategic transaction.
